Evaluation of the first potent and highly selective inhibitor of ATR kinase: An approach to selectively sensitize cancer cells to ionizing radiation and hypoxia

被引：0
|
作者：
McKenna, Gillies [1 ]
Brunner, Thomas [1 ]
Charlton, Peter [2 ]
Fokas, Emmanouil [1 ]
Hammond, Ester [1 ]
Mangan, Matthew [2 ]
Olcina, Monica [1 ]
Pires, Isabel [1 ]
Pollard, John [2 ]
Prevo, Remko [1 ]
Reaper, Philip [2 ]
机构：
[1] Univ Oxford, Gray Inst Radiat Oncol & Biol, Oxford, England
[2] Vertex Pharmaceut Europe Ltd, Abingdon, Oxon, England
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2012-5501
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5501
引用
收藏
页数：1
相关论文
共 48 条
  • [41] First-in-class, highly BDII-selective BET family inhibitor ABBV-744 displays potent anti-tumor activity in androgen receptor positive prostate cancer models and an improved tolerability profile
    Faivre, Emily J.
    Wilcox, Denise
    Mai Ha-Bui
    Hessler, Paul
    Sehgal, Vasudha
    Lu, Xin
    Uziel, Tamar
    Mehta, Gaurav
    Albert, Daniel H.
    McDaniel, Keith
    Kati, Warren
    Shen, Yu
    CANCER RESEARCH, 2018, 78 (13)
  • [42] Discovery of JS']JSI-124 (Cucurbitacin I), a selective janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice
    Blaskovich, MA
    Sun, JZ
    Cantor, A
    Turkson, J
    Jove, R
    Sebti, SM
    CANCER RESEARCH, 2003, 63 (06) : 1270 - 1279
  • [43] Preclinical evaluation of LYS6K1, a novel, highly selective, orally bioavailable inhibitor of p70 S6 kinase currently in phase I clinical trials for cancer
    Geeganage, Sandaruwan
    Sams, Lillian L.
    Joseph, Sajan
    Brail, Leslie
    Wang, Tao
    Rodgers, George
    Akunda, Jackie
    Huang, Jianping
    Perkins, Everett J.
    Ajamie, Rose
    CANCER RESEARCH, 2010, 70
  • [44] First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results.
    Di Giacomo, Anna Maria
    Santangelo, Federica
    Amato, Giovanni
    Simonetti, Elena
    Graham, Jill
    Lahn, Michael M. F.
    Van der Veen, Lars Anders
    Johnson, Zoe
    Pickering, Catherine Anne
    Durini, Marco
    Tan, Ziyang
    Tadepally, Lakshmikanth
    Brodin, Petter
    Occhipinti, Mariaelena
    Simonelli, Matteo
    Carlo-Stella, Carmelo
    Santoro, Armando
    Spiliopoulou, Pavlina
    Evans, T. R. Jeffry
    Maio, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Pre-clinical evaluation of LYS6KAKT1, a novel, highly selective, orally bioavailable dual inhibitor of p70 S6 Kinase and AKT currently in phase I clinical trials for cancer
    Geeganage, S.
    Sams, L.
    Joseph, S.
    Shepherd, T.
    Dally, R.
    Brail, L.
    Wang, T.
    Capen, A.
    Rodgers, G.
    Perkins, E.
    EJC SUPPLEMENTS, 2010, 8 (07): : 28 - 28
  • [46] BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust in vivo antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC).
    Lim, Sun Min
    Park, Chae Won
    Zhang, Zhuo
    Woessner, Rich
    Dineen, Tom
    Stevison, Faith
    Hsieh, John
    Eno, Meredith
    Wilson, Doug
    Campbell, John
    Utt, Caitlin
    Albayya, Faris
    Lamontagne, Nicolas
    Dorsch, Marion
    Hoeflich, Klaus
    Cho, Byoung Chul
    Schalm, Stefanie
    CANCER RESEARCH, 2021, 81 (13)
  • [47] A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
    Coleman, Robert L.
    Sill, Michael W.
    Bell-McGuinn, Katherine
    Aghajanian, Carol
    Gray, Heidi J.
    Tewari, Krishnansu S.
    Rubin, Steven C.
    Rutherford, Thomas J.
    Chan, John K.
    Chen, Alice
    Swisher, Elizabeth M.
    GYNECOLOGIC ONCOLOGY, 2015, 137 (03) : 386 - 391
  • [48] Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-β Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent
    Jin, Cheng Hua
    Krishnaiah, Maddeboina
    Sreenu, Domalapally
    Subrahmanyam, Vura B.
    Rao, Kota S.
    Lee, Hwa Jeong
    Park, So-Jung
    Park, Hyun-Ju
    Lee, Kiho
    Sheen, Yhun Yhong
    Kim, Dae-Kee
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (10) : 4213 - 4238
12345